Concepedia

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

Gϋnter von Minckwitz, Wolfgang Schmitt, Sibylle Loibl, Berit Müller, Jens‐Uwe Blohmer, Bruno V. Sinn, Holger Eidtmann, W. Eiermann, Bernd Gerber, Hans Tesch,

Clinical Cancer Research · 2013 · 173 citations · 30 references

DOIFull text

Open access

Abstract

Posttreatment Ki67 levels provide prognostic information for patients with hormone-receptor-positive breast cancer and residual disease after neoadjuvant chemotherapy. Levels were not prognostic for outcome after response-guided chemotherapy. High posttreatment Ki67 indicates the need for innovative postneoadjuvant treatments.

References

30

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

Johannes Gerdes, Ulrich Schwab, Hilmar Lemke et al. · International Journal of Cancer · 1983 · 2.8K citations

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer et al. · Journal of Clinical Oncology · 2012 · 2.6K citations

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

M. Dowsett, Torsten O. Nielsen, Roger A’Hern et al. · JNCI Journal of the National Cancer Institute · 2011 · 2K citations · Full text

Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System

Clifford A. Hudis, William E. Barlow, Joseph P. Costantino et al. · Journal of Clinical Oncology · 2007 · 860 citations · Full text

Reporting Recommendations for Tumor Marker Prognostic Studies

Lisa M. McShane, Douglas G. Altman, Willi Sauerbrei et al. · Journal of Clinical Oncology · 2005 · 770 citations · Full text

, , +15